Previous close | 231.68 |
Open | 232.27 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 231.01 - 234.59 |
52-week range | 231.01 - 286.33 |
Volume | |
Avg. volume | 3,814 |
Market cap | 63.233B |
Beta (5Y monthly) | 0.46 |
PE ratio (TTM) | 0.37 |
EPS (TTM) | 6.33 |
Earnings date | 02 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
BD (BDX) announces the commercial launch of its new single-cell research tool, BD Rhapsody ATAC-Seq Assay, to help researchers understand DNA regulation.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial launch of a new single-cell research tool to help scientists better understand how the molecular machinery within a cell functions and how it regulates changes in a cell that can lead to cancer and other diseases.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it plans to host webcasts to discuss quarterly financial results on the following dates: